市場調查報告書
商品編碼
915411

β地中海型貧血 - 市場洞察,流行病學,市場預測 2028年

Beta-thalassemia - Market Insights, Epidemiology and Market Forecast - 2028

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 170 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

新興10個國家(土耳其、俄羅斯、哥倫比亞、巴西、阿根廷、墨西哥、沙烏地阿拉伯、阿拉伯聯合大公國、中國、台灣)的2017年的β地中海型貧血的患病數6萬4,655人,同年的市場規模估算為2億110萬美元。

本報告提供新興10個國家(土耳其、俄羅斯、哥倫比亞、巴西、阿根廷、墨西哥、沙烏地阿拉伯、阿拉伯聯合大公國、中國、台灣)的β地中海型貧血市場調查,疾病概要,已上市治療藥及新藥的簡介,以整體及各國的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 市場概要:β地中海型貧血

  • 市場佔有率和分佈(實在數值)
  • 市場佔有率與分佈(預測值)

第3章 疾病背景和概要

  • 簡介
  • 類型
  • 分子遺傳學
  • 原因和危險因素
  • 關聯的併發症
  • 病因
  • 症狀
  • 病理生理學
  • 臨床症狀
  • 診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • 新興10個國家的β地中海型貧血的診斷患病數

第5章 β地中海型貧血的流行病學:各國

  • 假設和根據
  • 中國
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 台灣
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 沙烏地阿拉伯
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 阿拉伯聯合大公國
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 土耳其
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 俄羅斯
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 哥倫比亞
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 巴西
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 阿根廷
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 墨西哥
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症

第6章 β地中海型貧血的治療和管理

  • 輸血療法
  • 鐵螫合物療法
  • 鐵過剩症的治療
  • 骨髓及臍帶血移植
  • 胎兒血紅素誘導
  • 基因治療

第7章 未滿足需求

第8章 β地中海型貧血的治療貢獻的組織

第9章 關鍵意見領袖的意見:β地中海型貧血

第10章 案例研究

第11章 已上市治療藥

  • Desferal:Novartis
    • 產品說明
    • 法規的里程碑
    • 非專利處方藥的可得性
    • 優點與缺點
    • 產品簡介
  • Exjade:Novartis
  • Ferrirpox(deferiprone):Apotex

第12章 新藥

  • LentiGlobin BB305:BlueBird Bio
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • ACE-536:Acceleron Pharma/Celgene Corporation
  • PTG-300:Protagonist Therapeutics
  • ACE-011(Sotatercept):Acceleron Pharma / Celgene Corporation
  • LJPC-401:La Jolla Pharmaceutical Company

第13章 其他潛力治療藥物

  • Tipadena(Thiotepa):Adienne SA
    • 產品概要
    • 產品簡介

第14章 新興10個國家的β地中海型貧血市場分析

  • 主要調查結果
  • 新興10個國家的市場規模
    • 市場規模:各治療藥物

第15章 β地中海型貧血市場預測:各國

  • 市場預測新興10個國家
  • 中國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 台灣
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 土耳其
  • 俄羅斯
  • 哥倫比亞
  • 巴西
  • 阿根廷
  • 墨西哥

第16章 市場障礙

第17章 市場成長要素

第18章 附錄

  • 報告方法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

目錄
Product Code: DIMI0688

DelveInsight's 'Beta-thalassemia (B-thal) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of B-thal in the Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Beta-thalassemia (B-thal) from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • Turkey, Russia, China and Taiwan
  • Latin-America(Colombia, Brazil, Argentina, Mexico)
  • Middle-east (Saudi Arabia, UAE)

Study Period: 2017-2028

Beta-thalassemia (B-thal) - Disease Understanding and Treatment Algorithm

Beta-thalassemia is an inherited disorder that is a result of various mutations (over 200 disease-causing mutations have been identified) or, rarely, deletions of the beta-globin gene (HbB) on chromosome 11. About three percent of adult hemoglobin is made of alpha and delta chains. Just as with beta-thalassemia, mutations that affect the ability of the delta gene to produce delta chains can occur leading to delta thalassemia. Beta-thalassemia includes three main forms; Thalassemia Major variably referred to as "Cooley's Anemia" and "Mediterranean Anemia", Thalassemia Intermediate and Thalassemia Minor also called "beta-thalassemia carrier", "beta-thalassemia trait," or "heterozygous beta-thalassemia".

The DelveInsight Beta-thalassemia (B-thal) market report gives the thorough understanding of the Beta-thalassemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Beta-thalassemia in the 10 emerging markets.

Beta-thalassemia Epidemiology

The Beta-thalassemia (B-thal) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging market countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of B-thal, total diagnosed prevalence, diagnosed prevalence by disease type and complications associated with B-thal) scenario of Beta-thalassemia (B-thal) in the 10EM covering Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan and China from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Beta-thalassemia (B-thal) in 10EM was found to be 64,655, in the year 2017.

Beta-thalassemia Drug Chapters

This segment of the Beta-thalassemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Blood-transfusion Therapies form the mainstay of treatment landscape of Beta-thalassemia despite major limitations. The primary hindrance lies in the fact that there is major chances of iron overload, heart failure, arrhythmias, cirrhosis, hepatocellular carcinoma, osteoporosis, stunted growth, thrombophilia, diabetes, hyper and hypo thyroidism and gonadism etc. Despite these limitations, iron chelators are the treatment of choice and generate the maximum amount of revenue.

Beta-thalassemia Market Outlook

The Beta-thalassemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Beta-thalassemia in 10EM was found to be USD 201.10 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 10EM, China accounts for the largest market size of Beta-thalassemia, in comparison to other emerging market countries.

Beta-thalassemia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Beta-thalassemia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Beta-thalassemia Report Key Strengths

  • 10 Year Forecast
  • 10EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Beta-thalassemia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Beta-thalassemia market
  • Organize sales and marketing efforts by identifying the best opportunities for Beta-thalassemia market
  • To understand the future market competition in the Beta-thalassemia market.

Table of Contents

1 Key Insights

2 B-thalassemia Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of B -thalassemia in 2017
  • 2.2 Market Share (%) Distribution of B -thalassemia in 2028

3 Disease Background and Overview

  • 3.1 Introduction
  • 3.2 Types
  • 3.3 Molecular Genetics
  • 3.4 Causes and risk factors
  • 3.5 Complications associated with Beta-thalassemia
  • 3.6 Etiology
  • 3.7 Symptoms
  • 3.8 Pathophysiology
  • 3.9 Clinical Presentation of Beta-Thalassemia
  • 3.1 Diagnosis

4 Epidemiology and Patient Population

  • 4.1 Key Findings
  • 4.2 Total Diagnosed Prevalence of B-thal in 10 Emerging Markets

5 Country Wise-Epidemiology of Beta-Thal

  • 5.1 Assumptions and Rationale
  • 5.2 China
    • 5.2.1 Total Prevalent Cases of B-thal in China
    • 5.2.2 Diagnosed Prevalence of B-thal in China
    • 5.2.3 Diagnosed B-thal Patients by Disease Type in China
    • 5.2.4 Complications of B-thalassemia Patients in China
  • 5.3 Taiwan
    • 5.3.1 Total Prevalent Cases of B-thal in Taiwan
    • 5.3.2 Diagnosed Prevalence of B-thal in Taiwan
    • 5.3.3 Diagnosed B-thal Patients by Disease Type in Taiwan
    • 5.3.4 Complications of B-thalassemia Patients in Taiwan
  • 5.4 Saudi Arabia
    • 5.4.1 Total Prevalent Cases of B-thal in Saudi Arabia
    • 5.4.2 Diagnosed Prevalence of B-thal in Saudi Arabia
    • 5.4.3 Diagnosed B-thal Patients by Disease Type in Saudi Arabia
    • 5.4.4 Complications of B-thalassemia Patients in Saudi Arabia
  • 5.5 UAE
    • 5.5.1 Total Prevalent Cases of B-thal in UAE
    • 5.5.2 Diagnosed Prevalence of B-thal in UAE
    • 5.5.3 Diagnosed B-thal Patients by Disease Type in UAE
    • 5.5.4 Complications of B-thalassemia Patients in UAE
  • 5.6 Turkey
    • 5.6.1 Total Prevalent Cases of B-thal in Turkey
    • 5.6.2 Diagnosed Prevalence of B-thal in Turkey
    • 5.6.3 Diagnosed B-thal Patients by Disease Type in Turkey
    • 5.6.4 Complications of B-thalassemia Patients in Turkey
  • 5.7 Russia
    • 5.7.1 Total Prevalent Cases of B-thal in Russia
    • 5.7.2 Diagnosed Prevalence of B-thal in Russia
    • 5.7.3 Diagnosed B-thal Patients by Disease Type in Russia
    • 5.7.4 Complications of B-thalassemia Patients in Russia
  • 5.8 Colombia
    • 5.8.1 Total Prevalent Cases of B-thal in Colombia
    • 5.8.2 Diagnosed Prevalence of B-thal in Colombia
    • 5.8.3 Diagnosed B-thal Patients by Disease Type in Colombia
    • 5.8.4 Complications of B-thalassemia Patients in Colombia
  • 5.9 Brazil
    • 5.9.1 Total Prevalent Cases of B-thal in Brazil
    • 5.9.2 Diagnosed Prevalence of B-thal in Brazil
    • 5.9.3 Diagnosed B-thal Patients by Disease Type in Brazil
    • 5.9.4 Complications of B-thalassemia Patients in Brazil
  • 5.1 Argentina
    • 5.10.1 Total Prevalent Cases of B-thal in Argentina
    • 5.10.2 Diagnosed Prevalence of B-thal in Argentina
    • 5.10.3 Diagnosed B-thal Patients by Disease Type in Argentina
    • 5.10.4 Complications of B-thalassemia Patients in Argentina
  • 5.11 Mexico
    • 5.11.1 Total Prevalent Cases of B-thal in Mexico
    • 5.11.2 Diagnosed Prevalence of B-thal in Mexico
    • 5.11.3 Diagnosed B-thal Patients by Disease Type in Mexico
    • 5.11.4 Complications of B-thalassemia Patients in Mexico

6 Treatment and Management of Beta-thalassemia

  • 6.1 Transfusion therapy
  • 6.2 Iron Chelation Therapy
  • 6.3 Treatment of Iron-overload Complications
  • 6.4 Bone Marrow and Cord Blood Transplantation
  • 6.5 Fetal Hemoglobin Induction
  • 6.6 Gene therapy

7 Unmet Needs

8 Organizations contributing towards Beta-thalassemia

9 KOL Views: Beta-thalassemia

10 Case Studies

  • 10.1 Quality of Life and Depression in Turkish Patients with Beta-thalassemia Major: A Cross-Sectional Study
  • 10.2 Very mild forms of Hb S/beta+-thalassemia in Brazilian children
  • 10.3 Prevalence of Beta-thalassemia trait in premarital screening in Al-Hassa, Saudi Arabia
  • 10.4 Deferiprone or Deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan
  • 10.5 Molecular prenatal diagnosis of alpha and beta thalassemia in pregnant Hakka women in southern China

11 Marketed Drugs

  • 11.1 Desferal: Novartis
    • 11.1.1 Product Description
    • 11.1.2 Regulatory Milestones
    • 11.1.3 Generic Availability
    • 11.1.4 Advantages & Disadvantages
    • 11.1.5 Product Profile
  • 11.2 Exjade: Novartis
    • 11.2.1 Product Description
    • 11.2.2 Regulatory Milestones
    • 11.2.3 Generic Availability
    • 11.2.4 Advantages & Disadvantages
    • 11.2.5 Product Profile
  • 11.3 Ferrirpox (deferiprone): Apotex
    • 11.3.1 Drug Description
    • 11.3.2 Regulatory Milestones
    • 11.3.3 Advantages & Disadvantages
    • 11.3.4 Product Profile

12 Emerging Therapies

  • 12.1 LentiGlobin BB305: BlueBird Bio
    • 12.1.1 Product Description
    • 12.1.2 Other Development Activities
    • 12.1.3 Clinical Development
      • 12.1.3.1 Clinical Trials Information
    • 12.1.4 Safety and Efficacy
    • 12.1.5 Product Profile
  • 12.2 ACE-536: Acceleron Pharma/Celgene Corporation
    • 12.2.1 Product Description
    • 12.2.2 Other Developmental Activities
    • 12.2.3 Clinical Development
      • 12.2.3.1 Clinical Trials Information
    • 12.2.4 Safety and Efficacy
    • 12.2.5 Product Profile
  • 12.3 PTG-300: Protagonist Therapeutics
    • 12.3.1 Product Description
    • 12.3.2 Other Developmental Activities
    • 12.3.3 Clinical Development
      • 12.3.3.1 Clinical Trials Information
    • 12.3.4 Safety and Efficacy
    • 12.3.5 Product Profile
  • 12.4 ACE-011 (Sotatercept): Acceleron Pharma/Celgene Corporation
    • 12.4.1 Product Description
    • 12.4.2 Other Developmental Activities
    • 12.4.3 Clinical Development
      • 12.4.3.1 Clinical Trials Information
    • 12.4.4 Safety and Efficacy
    • 12.4.5 Product Profile
  • 12.5 LJPC-401: La Jolla Pharmaceutical Company
    • 12.5.1 Product Description
    • 12.5.2 Other Developmental Activities
    • 12.5.3 Clinical development
      • 12.5.3.1 Clinical Trials Information
    • 12.5.4 Safety and Efficacy
    • 12.5.5 Product Profile

13 Other Promising Therapies

  • 13.1 Tipadena (Thiotepa): Adienne SA
    • 13.1.1 Product description
    • 13.1.2 Product Profile

14 Beta-thalassemia : 10 EM Market Analysis

  • 14.1 Key Findings
  • 14.2 Market Size of B-thalassemia in 10 EM
    • 14.2.1 Market Size of B-thal by Therapies

15 Market Outlook by Country

  • 15.1 Emerging Markets: Market Outlook
  • 15.2 China
    • 15.2.1 Total Market Size of Beta-thalassemia
    • 15.2.2 Market Size of Beta-thalassemia by Therapies
  • 15.3 Taiwan
    • 15.3.1 Total Market Size of Beta-thalassemia
    • 15.3.2 Market Size of Beta-thalassemia by Therapies
  • 15.4 Saudi Arabia
    • 15.4.1 Total Market Size of Beta-thalassemia
    • 15.4.2 Market Size of Beta-thalassemia by Therapies
  • 15.5 UAE
    • 15.5.1 Total Market Size of Beta-thalassemia
    • 15.5.2 Market Size of Beta-thalassemia by Therapies
  • 15.6 Turkey
    • 15.6.1 Total Market Size of Beta-thalassemia
    • 15.6.2 Market Size of Beta-thalassemia by Therapies
  • 15.7 Russia
    • 15.7.1 Total Market Size of Beta-thalassemia
    • 15.7.2 Market Size of Beta-thalassemia by Therapies
  • 15.8 Colombia
    • 15.8.1 Total Market Size of Beta-thalassemia
    • 15.8.2 Market Size of Beta-thalassemia by Therapies
  • 15.9 Brazil
    • 15.9.1 Total Market Size of Beta-thalassemia
    • 15.9.2 Market Size of Beta-thalassemia by Therapies
  • 15.1 Argentina
    • 15.10.1 Total Market Size of Beta-thalassemia
    • 15.10.2 Market Size of Beta-thalassemia by Therapies
  • 15.11 Mexico
    • 15.11.1 Total Market Size of Beta-thalassemia
    • 15.11.2 Market Size of Beta-thalassemia by Therapies

16 Market Barriers

17 Market Drivers

18 Appendix

  • 18.1 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

List of Tables

  • Table 1: Difference between Beta-thalassemia major and intermediate based on different parameters
  • Table 2: Diagnosed Prevalence of B-thal in 10 Emerging Markets (2017-2028)
  • Table 3: Total Prevalent Cases B-thal in China (2017-2028)
  • Table 4: Diagnosed Prevalence of B-thal in China (2017-2028)
  • Table 5: Diagnosed B-thal Patients by Disease Type in China (2017-2028)
  • Table 6: Complications of B-thalassemia Patients in China (2017-2028)
  • Table 7: Total Prevalence Cases of B-thal in Taiwan (2017-2028)
  • Table 8: Diagnosed Prevalence of B-thal by Types in Taiwan (2017-2028)
  • Table 9: Diagnosed B-thal Patients by Disease Type in Taiwan (2017-2028)
  • Table 10: Complications of B-thalassemia Patients in Taiwan (2017-2028)
  • Table 11: Total Prevalence Cases of B-thal in Saudi Arabia (2017-2028)
  • Table 12: Diagnosed Prevalence of B-thal in Saudi Arabia (2017-2028)
  • Table 13: Diagnosed B-thal Patients by Disease Type in Saudi Arabia (2017-2028)
  • Table 14: Complications of B-thalassemia Patients in Saudi Arabia (2017-2028)
  • Table 15: Total Prevalence Cases of B-thal in UAE (2017-2028)
  • Table 16: Diagnosed Prevalence of B-thal in UAE (2017-2028)
  • Table 17: Diagnosed B-thal Patients by Disease Type in UAE (2017-2028)
  • Table 18: Complications of B-thalassemia Patients in UAE (2017-2028)
  • Table 19: Total Prevalence Cases of B-thal in Turkey (2017-2028)
  • Table 20: Diagnosed Prevalence of B-thal in Turkey (2017-2028)
  • Table 21: Diagnosed B-thal Patients by Disease Type in Turkey (2017-2028)
  • Table 22: Complications of B-thalassemia Patients in Turkey (2017-2028)
  • Table 23: Total Prevalence Cases of B-thal in Russia (2017-2028)
  • Table 24: Diagnosed Prevalence of B-thal in Russia (2017-2028)
  • Table 25: Diagnosed B-thal Patients by Disease Type in Russia (2017-2028)
  • Table 26: Complications of B-thalassemia Patients in Russia (2017-2028)
  • Table 27: Total Prevalence Cases of B-thal in Colombia (2017-2028)
  • Table 28: Diagnosed Prevalence of B-thal in Colombia (2017-2028)
  • Table 29: Diagnosed B-thal Patients by Disease Type in Colombia (2017-2028)
  • Table 30: Complications of B-thalassemia Patients in Colombia (2017-2028)
  • Table 31: Total Prevalence Cases of B-thal in Brazil (2017-2028)
  • Table 32: Diagnosed Prevalence of B-thal in Brazil (2017-2028)
  • Table 33: Diagnosed B-thal Patients by Disease Type in Brazil (2017-2028)
  • Table 34: Complications of B-thalassemia Patients in Brazil (2017-2028)
  • Table 35: Total Prevalence Cases of B-thal in Argentina (2017-2028)
  • Table 36: Diagnosed Prevalence of B-thal in Argentina (2017-2028)
  • Table 37: Diagnosed B-thal Patients by Disease Type in Argentina (2017-2028)
  • Table 38: Complications of B-thalassemia Patients in Argentina (2017-2028)
  • Table 39: Total Prevalence Cases of B-thal in Mexico (2017-2028)
  • Table 40: Diagnosed Prevalence of B-thal in Mexico (2017-2028)
  • Table 41: Diagnosed B-thal Patients by Disease Type in Mexico (2017-2028)
  • Table 42: Complications of B-thalassemia Patients in Mexico (2017-2028)
  • Table 43: Comparison of three leading iron chelators for treatment of beta-thalassemia
  • Table 44: Frequencies of various complications and treatment of Beta-thalassemia
  • Table 45: Organizations contributing toward Beta-thalassemia
  • Table 46: LentiGlobin BB305, Clinical Trial Description 2019
  • Table 47: ACE-536, Clinical Trial Description 2019
  • Table 48: PGT-300, Clinical Trial Description 2019
  • Table 49: ACE-011, Clinical Trial Description 2019
  • Table 50: LJPC-401, Clinical Trial Description 2019
  • Table 51: Total Market Size of B-thal in 10 Emerging Markets in USD Million (2017-2028)
  • Table 52: Total Market Size of B-thal by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Table 53: Total Market Size of B-thal in China, USD Million (2017-2028)
  • Table 54: China Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 55: Total Market Size of B-thal in Taiwan, USD Million (2017-2028)
  • Table 56: Taiwan Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 57: Total Market Size of B-thal in Saudi Arabia, USD Million (2017-2028)
  • Table 58: Saudi Arabia Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 59: Total Market Size of B-thal in UAE, USD Million (2017-2028)
  • Table 60: UAE Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 61: Total Market Size of B-thal in Turkey, USD Million (2017-2028)
  • Table 62: Turkey Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 63: Total Market Size of B-thal in Russia, USD Million (2017-2028)
  • Table 64: Russia Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 65: Total Market Size of B-thal in Colombia, USD Million (2017-2028)
  • Table 66: Colombia Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 67: Total Market Size of B-thal in Brazil, USD Million (2017-2028)
  • Table 68: Brazil Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 69: Total Market Size of B-thal in Argentina, USD Million (2017-2028)
  • Table 70: Argentina Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Table 71: Total Market Size of B-thal in Mexico, USD Million (2017-2028)
  • Table 72: Mexico Market Size of B-thal by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Chromosome 11
  • Figure 2: Red blood cells
  • Figure 3: Classification of Beta-thalassemia by
  • Figure 4: Inheritance pattern of Beta-thalassemia
  • Figure 5: Possible complications associated with Beta-thalassemia
  • Figure 6: Symptoms of Beta-thalassemia
  • Figure 7: Pathophysiology of Beta-thalassemia
  • Figure 8: Clinical and Psychosocial concerns among patient's in different age-groups
  • Figure 9: Diagnostic algorithm of Beta-thalassemia
  • Figure 10: Diagnosed Prevalence of B-thal in 10 Emerging Markets (2017-2028)
  • Figure 11: Total Prevalent Cases of B-thal in China (2017-2028)
  • Figure 12: Diagnosed Prevalence of B-thal in China (2017-2028)
  • Figure 13: Diagnosed B-thal Patients by Disease Type in China (2017-2028)
  • Figure 14: Complications of B-thalassemia Patients in China (2017-2028)
  • Figure 15: Total Prevalence Cases of B-thal in Taiwan (2017-2028)
  • Figure 16: Diagnosed Prevalence of B-thal by Types in Taiwan (2017-2028)
  • Figure 17: Diagnosed B-thal Patients by Disease Type in Taiwan (2017-2028)
  • Figure 18: Complications of B-thalassemia Patients in Taiwan (2017-2028)
  • Figure 19: Total Prevalence Cases of B-thal in Saudi Arabia (2017-2028)
  • Figure 20: Diagnosed Prevalence of B-thal in Saudi Arabia (2017-2028)
  • Figure 21: Diagnosed B-thal Patients by Disease Type in Saudi Arabia (2017-2028)
  • Figure 22: Complications of B-thalassemia Patients in Saudi Arabia (2017-2028)
  • Figure 23: Total Prevalence Cases of B-thal in UAE (2017-2028)
  • Figure 24: Diagnosed Prevalence of B-thal in UAE (2017-2028)
  • Figure 25: Diagnosed B-thal Patients by Disease Type in UAE (2017-2028)
  • Figure 26: Complications of B-thalassemia Patients in UAE (2017-2028)
  • Figure 27: Total Prevalence Cases of B-thal in Turkey (2017-2028)
  • Figure 28: Diagnosed Prevalence of B-thal in Turkey (2017-2028)
  • Figure 29: Diagnosed B-thal Patients by Disease Type in Turkey (2017-2028)
  • Figure 30: Complications of B-thalassemia Patients in Turkey (2017-2028)
  • Figure 31: Total Prevalence Cases of B-thal in Russia (2017-2028)
  • Figure 32: Diagnosed Prevalence of B-thal in Russia (2017-2028)
  • Figure 33: Diagnosed B-thal Patients by Disease Type in Russia (2017-2028)
  • Figure 34: Complications of B-thalassemia Patients in Russia (2017-2028)
  • Figure 35: Total Prevalence Cases of B-thal in Colombia (2017-2028)
  • Figure 36: Diagnosed Prevalence of B-thal in Colombia (2017-2028)
  • Figure 37: Diagnosed B-thal Patients by Disease Type in Colombia (2017-2028)
  • Figure 38: Complications of B-thalassemia Patients in Colombia (2017-2028)
  • Figure 39: Total Prevalence Cases of B-thal in Brazil (2017-2028)
  • Figure 40: Diagnosed Prevalence of B-thal in Brazil (2017-2028)
  • Figure 41: Diagnosed B-thal Patients by Disease Type in Brazil (2017-2028)
  • Figure 42: Complications of B-thalassemia Patients in Brazil (2017-2028)
  • Figure 43: Total Prevalence Cases of B-thal in Argentina (2017-2028)
  • Figure 44: Diagnosed Prevalence of B-thal in Argentina (2017-2028)
  • Figure 45: Diagnosed B-thal Patients by Disease Type in Argentina (2017-2028)
  • Figure 46: Complications of B-thalassemia Patients in Argentina (2017-2028)
  • Figure 47: Total Prevalence Cases of B-thal in Mexico (2017-2028)
  • Figure 48: Diagnosed Prevalence of B-thal in Mexico (2017-2028)
  • Figure 49: Diagnosed B-thal Patients by Disease Type in Mexico (2017-2028)
  • Figure 50: Complications of B-thalassemia Patients in Mexico (2017-2028)
  • Figure 51: Overview of current management of Beta-Thalassemia
  • Figure 52: Beta-thalassemia and its severity based on transfusion dependency
  • Figure 53: Amelioration of ROS by iron chelators and antioxidants
  • Figure 54: Unmet needs
  • Figure 55: Total Market Size of B-thal in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 56: Total Market Size of B-thal by Therapies in 10 Emerging Markets in USD Million (2017-2028)
  • Figure 57: Total Market Size of B-thal in China, USD Million (2017-2028)
  • Figure 58: China Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 59: Total Market Size of B-thal in Taiwan, USD Million (2017-2028)
  • Figure 60: Taiwan Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 61: Total Market Size of B-thal in Saudi Arabia, USD Million (2017-2028)
  • Figure 62: Saudi Arabia Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 63: Total Market Size of B-thal in UAE, USD Million (2017-2028)
  • Figure 64: UAE Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 65: Total Market Size of B-thal in Turkey, USD Million (2017-2028)
  • Figure 66: Turkey Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 67: Total Market Size of B-thal in Russia, USD Million (2017-2028)
  • Figure 68: Russia Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 69: Total Market Size of B-thal in Colombia, USD Million (2017-2028)
  • Figure 70: Colombia Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 71: Total Market Size of B-thal in Brazil, USD Million (2017-2028)
  • Figure 72: Brazil Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 73: Total Market Size of B-thal in Argentina, USD Million (2017-2028)
  • Figure 74: Argentina Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 75: Total Market Size of B-thal in Mexico, USD Million (2017-2028)
  • Figure 76: Mexico Market Size of B-thal by Therapies in USD Million (2017-2028)
  • Figure 77: Market Barriers
  • Figure 78: Market Drivers